Humacyte HUMA 深 滬
等待開盤 10-29 09:30:00 美东时间
0.4701
+0.024
+5.33%
華盛通- 最 高0.4794
- 今 開0.45
- 成交量 265.75万股
- 最 低 0.4319
- 昨 收 0.4463
- 總市值 1.31亿
- 52周最高 1.525
- 市盈率 靜 --
- 換手率 0.96%
- 52周最低 0.337
- 委 比 -92.92%
- 總股本 2.78亿
- 歷史最高 17.45
- 量 比 0.79
- 振 幅 10.64%
- 歷史最低 0.337
- 每 手 1
- 風險率 0.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026
10-23 20:03
Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest. DURHAM, N.C., Oct. 15, 2026 (GLOBE NEWSWIRE) -- ...
10-15 21:18
估值跌至十年低点！巴克莱首次覆盖26家美股医疗科技股，首选史赛克(SYK.US)等
巴克莱分析师Christopher Pasquale周二首次覆盖26家美股医疗科技公司，并将史赛克(SYK.US)和雅培(ABT.US)列入大盘医疗科技股推荐名...
10-08 13:58
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5
Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.
10-07 20:45
Humacyte Bolsters Board for Upcoming Commercial Expansion
Humacyte ( ($HUMA) ) has shared an announcement. On September 22, 2026, Humacyt...
09-29 05:14
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. has announced the addition of Scott Coward and Paul Kuznik to its Board of Directors. Both bring extensive experience in commercialization, leadership, and global operations. Coward, formerly with Exact Sciences, has expertise in public company governance and legal affairs. Kuznik, a veteran in vascular healthcare, has led commercialization efforts in cardiovascular devices. Their加入 is expected to support Humacyte's ongoing product...
09-28 12:00
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte, Inc. announced that its CEO, Laura Niklason, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 11:00am ET. Management will also hold one-on-one meetings. The event will be webcast and a replay will be available on the company's website. Humacyte is developing bioengineered human tissues, including ATEVs, which have received FDA approval and are in la...
09-10 12:00
Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months
Extension for Symvess (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F). The expiration dating extension is supported by additional stability data demonstrating that Symvess continues to meet all established product q...
09-09 20:06
